Life-threatening delayed hyperhemolytic transfusion reaction in a patient with sickle cell disease: effective treatment with eculizumab followed by rituximab-Reference-Cited by-同舟云学术

Life-threatening delayed hyperhemolytic transfusion reaction in a patient with sickle cell disease: effective treatment with eculizumab followed by rituximab

Published:2015-05-18 Issue:10 Volume:55 Page:2398-2403
ISSN:0041-1132
Container-title:Transfusion
language:en
Short-container-title:Transfusion

Author:

Boonyasampant Mark¹,Weitz Ilene C.²,Kay Brian¹,Boonchalermvichian Chaiyaporn²,Liebman Howard A.²,Shulman Ira A.¹

Affiliation:

1. Department of Pathology; Los Angeles County-University of Southern California Medical Center

2. Jane Anne Nohl Division of Hematology; Department of Medicine; Keck School of Medicine; Los Angeles California

Publisher

Wiley

Subject

Hematology,Immunology,Immunology and Allergy

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/trf.13144/fullpdf

Reference27 articles.

1. Severe reactions associated with transfusion of patients with sickle cell disease;Garratty;Transfusion,1997

2. Delayed hemolytic transfusion reactions in sickle cell disease: simultaneous destruction of recipients’ red cells;King;Transfusion,1997

3. The sickle cell hemolytic transfusion reaction syndrome;Petz;Transfusion,1997

4. Delayed hemolytic transfusion reaction in sickle cell disease;Scheunemann;Am J Med Sci,2010

5. Hyperhemolysis syndrome in sickle cell disease: case report (recurrent episode) and literature review;Win;Transfusion,2008

Cited by 43 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Complement involvement in sickle cell disease;La Presse Médicale;2023-12

2. Complement biology for hematologists;American Journal of Hematology;2023-03-31

3. The Development and Consequences of Red Blood Cell Alloimmunization;Annual Review of Pathology: Mechanisms of Disease;2023-01-24

4. Adverse events of red blood cell transfusions in patients with sickle cell disease;Transfusion and Apheresis Science;2022-10

5. Long-term Use of Eculizumab for Prolonged Hemolysis Following a Delayed Hemolytic Transfusion Reaction in Pediatric Sickle Cell: A Case Report;The Journal of Pediatric Pharmacology and Therapeutics;2022-07-01